Results 141 to 150 of about 197,499 (175)

Long-Acting Growth Hormone: An Update

2015
After the introduction of recombinant human growth hormone (rhGH) in 1985, a myriad of children and adults have benefited from its growth-promoting and metabolic effects. Nowadays, current therapeutic regimens rely on daily subcutaneous GH injections that could be burdensome and inconvenient to pediatric patients.
Paul H, Saenger, Jorge, Mejia-Corletto
openaire   +2 more sources

The current state of long-acting growth hormone preparations for growth hormone therapy

Current Opinion in Endocrinology, Diabetes & Obesity, 2018
Purpose of review To discuss the rationale of developing long-acting growth hormone (LAGH) preparations, to describe the technologies designed to prolong GH action, and to address key issues regarding efficacy, safety, and monitoring while on treatment.
Kevin C J, Yuen, Bradley S, Miller, Beverly M K, Biller   +2 more
openaire   +2 more sources

Novel Long-Acting Crystal Formulation of Human Growth Hormone

Pharmaceutical Research, 2005
The aim of the study is to solve a significant challenge of extending the half-life of therapeutic proteins using crystalline biopharmaceuticals and without redesigning the molecules.Crystals of recombinant human growth hormone were coated with a monomolecular layer of positively charged poly(arginine). The pharmacokinetics and pharmacodynamics of this
Chandrika, Govardhan, Nazer, Khalaf, Chu W, Jung, Ben, Simeone, Amy, Higbie, Susan, Qu, Letha, Chemmalil, Sergey, Pechenov, Sujit K, Basu, Alexey L, Margolin   +9 more
openaire   +2 more sources

Long-Acting Growth Hormone Analogues

2011
Growth hormone (GH) is an anabolic cytokine hormone regulating linear growth in childhood and normal body composition in adults. The current therapeutic regimen for GH replacement requires once-daily subcutaneous injections which is inconvenient and expensive.
Alice Thorpe, Helen Freeman, Sarbendra L. Pradhananga, Ian R. Wilkinson, Richard J. M. Ross   +4 more
openaire   +1 more source

Long-Acting Human Growth Hormone Analogue by Noncovalent Albumin Binding

Bioconjugate Chemistry, 2018
The present work describes a series of human growth hormone (hGH) albumin binder conjugates with an extended in vivo half-life. A broad range of different conjugates were studied by varying the albumin binder structure and conjugation site. Conjugates were conveniently obtained by reductive alkylation or by alkylation to introduced cysteines using ...
Henrik S, Ramírez-Andersen, Carsten, Behrens, Jens, Buchardt, Johannes J, Fels, Charlotta G, Folkesson, Chen, Jianhe, Leif, Nørskov-Lauritsen, Per F, Nielsen, Mats, Reslow, Christian, Rischel, Jing, Su, Peter, Thygesen, Charlotte, Wiberg, Xin, Zhao, Xia, Wenjuan, Nils L, Johansen   +15 more
openaire   +2 more sources

Long-acting growth hormone in the treatment of children with growth hormone deficiency

Expert Review of Endocrinology & Metabolism
The introduction of long-acting formulations in recent years is changing the landscape of growth hormone (GH) therapy. Daily recombinant human GH (rhGH) has been the treatment of choice for children and adults with GH deficiency (GHD), since its approval in 1985. However, decreasing adherence to treatment over time has been identified as a cause of the
Iughetti, Lorenzo, Insalaco, Anna, Predieri, Barbara, Lucaccioni, Laura   +3 more
openaire   +3 more sources

Pituitary growth hormone suppression withlow-dosage, long-acting corticoid administration

The Journal of Pediatrics, 1968
Statural growth was inhibited in 16 patients with congenital adrenal hyperplasia who received 6α-methylprednisolone acelate in a biweekly, intramuscular, physiologic dosage regimen. The response of plasma growth hormone to induced hypoglycemia was found to be obliterated in 7 of these patients selected for study. Administration of cortisone acetate for
R S, Stempfel, B M, Sheikholislam, H E, Lebovitz, E, Allen, R C, Franks   +4 more
openaire   +2 more sources

Long-Acting Forms of Growth Hormone-Releasing Hormone and Growth Hormone: Effects in Normal Volunteers and Adults with Growth Hormone Deficiency

Hormone Research in Paediatrics, 2007
<i>Background:</i> Growth hormone (GH) replacement therapy in adults and children has found broad acceptance by endocrinologists and patients, but the need for daily injections remains a significant barrier to more widespread use. <i>Long-acting Formulations:</i> Several approaches have been taken to develop long-acting forms of
openaire   +2 more sources

Potent long-acting alkylated analogs of growth hormone-releasing factor.

Peptide research, 1992
Analogs of growth hormone-releasing factor-(1-29)-NH2 (GRF-29) involving derivatization with alkyl substituents at the N-terminus, with or without concomitant alkylation of basic amino acids within the peptide chain (lysine in positions 12 and 21), were synthesized using solid-phase methodology and tested for their ability to stimulate growth hormone ...
W A, Murphy, D H, Coy
openaire   +2 more sources

Potent long-acting growth hormone releasing factor analogues.

Annals of the New York Academy of Sciences, 1988
Amidated fragments 1 to 29 of human growth hormone releasing factor, (GRF1-29NH2), were designed to encompass modifications that could prevent degradation by exopeptidases. The NH2-terminus was blocked by either N-methylation of Tyr1 or by introduction of NMeDAla2 while the COOH-terminus was blocked by an N-ethylamide.
J, Rivier, C, Rivier, R, Galyean, G, Yammamoto, W, Vale   +4 more
openaire   +1 more source